Skip to main content
Clinical Trials/NCT03635294
NCT03635294
Completed
Not Applicable

Multi-Omics and IPSCs to Improve the Diagnosis of Rare Intellectual Disabilities

University Hospital, Angers6 sites in 1 country7 target enrollmentJanuary 9, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rare Intellectual Disabilities
Sponsor
University Hospital, Angers
Enrollment
7
Locations
6
Primary Endpoint
To evaluate the relevance and effectiveness of a multi-omics approach to the diagnosis of ID of unknown genetic origin.
Status
Completed
Last Updated
last year

Overview

Brief Summary

Background Genetic factors play a major role in intellectual disability (ID) but the underlying cause is not determined in many cases.

This proposal is the continuation of the previous interregional project HUGODIMS, the aim of which was to perform whole exome sequencing (WES) in 69 thoroughly selected simplex ID parent-child trios. Thanks to HUGODIMS consortium, the underlying genetic cause of ID was determined or highly suspected in 48 cases (69.5%) and 7 novel ID genes were identified.

Hypothesis Investigators hypothesize that an approach combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells would improve diagnosis of ID. The current proposal is therefore a proof-of concept project aiming at assessing the relevance and effectiveness of this multi-omics approach.

Aims and Methods Ten individuals with ID recruited through HUGODIMS, in whom WES have failed to identify pathogenic variants will be included.

The workflow is the following:

  1. Whole genome sequencing (WGS) (Nantes) of these 10 negative trios.

  2. Bio-informatics analyses

  3. In 3 WGS negative cases, 3 positive controls bearing distinct mutations in CAMK2a (a novel ID gene identified thanks to HUGODIMS), and 3 healthy negative controls:

    1. Derivation of induced pluripotent stem cell (iPSC)-derived neural progenitors (iPSC core facility at Nantes)
    2. Targeted and non-targeted metabolomics analyses performed on iPSC-derived neuronal cells (Angers)
    3. RNA sequencing performed on the 9 cell lines (Rennes)
    4. Morphological analyses of differentiated neuronal cell lines derived from 3 affected individuals and 3 positive controls bearing CMK2a mutations (Tours)
    5. Integration and validation of data from multi-omics and morphological approaches

Expected results and impact Investigatrors expect that this approach combining multi-omics and iPSC will help to improve diagnosis and understanding of genetic ID of unknown cause

Registry
clinicaltrials.gov
Start Date
January 9, 2019
End Date
February 11, 2020
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Angers
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 3 Whole Genome Sequencing negative cases
  • 3 positive controls bearing distinct mutations in CAMK2a

Exclusion Criteria

  • no informed consent/refusal

Outcomes

Primary Outcomes

To evaluate the relevance and effectiveness of a multi-omics approach to the diagnosis of ID of unknown genetic origin.

Time Frame: Day 1

Whole genome sequencing : de novo variants in non-coding regions of the genome, WGS will be performed using the HiSeq X Five System 5; Bionformatics analysis of WGS data; neuronal progenitors derived from iPSC

Secondary Outcomes

  • The assessment of metabolomics consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines(Day 1)
  • The assessment of morphological consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines(Day 1)

Study Sites (6)

Loading locations...

Similar Trials